Amgen (AMGN) Misses Q1 EPS by 35c, Revenues Miss; Reaffirms FY21 EPS/Revenues Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Amgen Reports First Quarter 2021 Financial Results
April 27, 2021 4:01 PM EDTTHOUSAND OAKS, Calif., April 27, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the first quarter of 2021. Key results include:
Total revenues decreased 4% to $5.9 billion in comparison to the first quarter of 2020, driven by lower net selling prices, partially offset by volume growth. These results reflect the cumulative, continuing negative effect of COVID-19 on patient visits and new patient diagnoses. Although product sales decreased 5%, volumes grew double digits or better for a number of products including Repatha® (evolocumab), Prolia® (denosumab), MVASI® (bevacizumab-awwb) and KANJINTI®... More